(919) 237-4897 info@t3dtherapeutics.com

Welcome to T3D Therapeutics

T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer’s disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease.

Fundamental to our approach is the recognition that Alzheimer’s disease (refs.1-5) is a neuro-metabolic disease and, as such, we must first address poor energy metabolism and dysfunctional lipid metabolism in the brain – brain ‘starvation’ – which leads to neurodegeneration and brain ‘strangulation’, as evidenced by plaques, tangles and inflammation of the brain (ref. 6).

The brain is the most metabolically active organ in the body and it relies on glucose, or sugar, for fuel (ref. 7). If the brain loses its ability to efficiently process sugar into energy and maintain lipid homeostasis, the brain becomes starved. This ‘starvation’ causes a wasting process that then leads to cognitive and motor function deficits – this is Alzheimer’s disease.

Our lead product candidate, T3D-959, is positioned to become a transformational therapy by targeting both the brain ‘starvation’ and ‘strangulation’ of Alzheimer’s disease and by treating multiple manifestations of the disease.


The brain accounts for only 2% of total body weight.


Oxygen is vital to metabolism. The adult brain uses 20% of the body's total oxygen consumption.


The brain is the organ with the highest level of energy metabolism. The brain uses 25% of total body glucose and 15% of the cardiac output in the resting awake state.

T3D-959 – A ‘First-in-Class’ Transformational Approach to Reverse Alzheimer’s Disease


Uniquely addresses the ‘starvation’ and ’strangulation’ of the brain found in Alzheimer’s disease


First drug to potentially improve memory, motor function and cognition


First drug to potentially improve multiple defects caused by Alzheimer’s disease

Contact Us